<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Maestas DR</submitter><funding>HHS | National Institutes of Health</funding><funding>NEI NIH HHS</funding><funding>NCATS NIH HHS</funding><funding>NIA NIH HHS</funding><funding>NIAID NIH HHS</funding><funding>U.S. Department of Defense</funding><funding>NCI NIH HHS</funding><funding>NIAMS NIH HHS</funding><funding>HHS | NIH | National Eye Institute</funding><pagination>e2211703120</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9974432</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>120(8)</volume><pubmed_abstract>The immune system is increasingly recognized as an important regulator of tissue repair. We developed a regenerative immunotherapy from the helminth &lt;i>Schistosoma mansoni&lt;/i> soluble egg antigen (SEA) to stimulate production of interleukin (IL)-4 and other type 2-associated cytokines without negative infection-related sequelae. The regenerative SEA (rSEA) applied to a murine muscle injury induced accumulation of IL-4-expressing T helper cells, eosinophils, and regulatory T cells and decreased expression of IL-17A in gamma delta (γδ) T cells, resulting in improved repair and decreased fibrosis. Encapsulation and controlled release of rSEA in a hydrogel further enhanced type 2 immunity and larger volumes of tissue repair. The broad regenerative capacity of rSEA was validated in articular jo</pubmed_abstract><journal>Proceedings of the National Academy of Sciences of the United States of America</journal><pubmed_title>Helminth egg derivatives as proregenerative immunotherapies.</pubmed_title><pmcid>PMC9974432</pmcid><funding_grant_id>DP1 AR076959</funding_grant_id><funding_grant_id>DP1AR076959</funding_grant_id><funding_grant_id>T32 CA153952</funding_grant_id><funding_grant_id>HHSN272201700014C</funding_grant_id><funding_grant_id>KL2 TR001429</funding_grant_id><funding_grant_id>W81XWH-19-1-0576</funding_grant_id><funding_grant_id>R01 EY029055</funding_grant_id><funding_grant_id>T32 AG058527</funding_grant_id><funding_grant_id>R01EY029055</funding_grant_id><pubmed_authors>Elisseeff JH</pubmed_authors><pubmed_authors>Pearce EJ</pubmed_authors><pubmed_authors>Pena AN</pubmed_authors><pubmed_authors>Ganguly S</pubmed_authors><pubmed_authors>Zhang H</pubmed_authors><pubmed_authors>Zack DJ</pubmed_authors><pubmed_authors>Mejia C</pubmed_authors><pubmed_authors>Sommerfeld SD</pubmed_authors><pubmed_authors>Nguyen HH</pubmed_authors><pubmed_authors>Anderson AE</pubmed_authors><pubmed_authors>Zhao L</pubmed_authors><pubmed_authors>Kelly SH</pubmed_authors><pubmed_authors>Andorko JI</pubmed_authors><pubmed_authors>Housseau F</pubmed_authors><pubmed_authors>Choi Y</pubmed_authors><pubmed_authors>Wang X</pubmed_authors><pubmed_authors>Woo J</pubmed_authors><pubmed_authors>Eric M</pubmed_authors><pubmed_authors>Chung L</pubmed_authors><pubmed_authors>Chin AF</pubmed_authors><pubmed_authors>Mejias JC</pubmed_authors><pubmed_authors>Hooks JST</pubmed_authors><pubmed_authors>Maestas DR</pubmed_authors><pubmed_authors>Krishnan K</pubmed_authors><pubmed_authors>Mahatme R</pubmed_authors><pubmed_authors>Han J</pubmed_authors><pubmed_authors>Berlinicke CA</pubmed_authors><pubmed_authors>Moore E</pubmed_authors><pubmed_authors>Pardoll DM</pubmed_authors></additional><is_claimable>false</is_claimable><name>Helminth egg derivatives as proregenerative immunotherapies.</name><description>The immune system is increasingly recognized as an important regulator of tissue repair. We developed a regenerative immunotherapy from the helminth &lt;i>Schistosoma mansoni&lt;/i> soluble egg antigen (SEA) to stimulate production of interleukin (IL)-4 and other type 2-associated cytokines without negative infection-related sequelae. The regenerative SEA (rSEA) applied to a murine muscle injury induced accumulation of IL-4-expressing T helper cells, eosinophils, and regulatory T cells and decreased expression of IL-17A in gamma delta (γδ) T cells, resulting in improved repair and decreased fibrosis. Encapsulation and controlled release of rSEA in a hydrogel further enhanced type 2 immunity and larger volumes of tissue repair. The broad regenerative capacity of rSEA was validated in articular jo</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Feb</publication><modification>2025-04-04T22:55:13.261Z</modification><creation>2025-04-04T22:55:13.261Z</creation></dates><accession>S-EPMC9974432</accession><cross_references><pubmed>36780522</pubmed><doi>10.1073/pnas.2211703120</doi></cross_references></HashMap>